NASDAQ · Financial Statements
Achilles Therapeutics plc (ACHL) Financial Statements
$1.48
NASDAQ: ACHL
Market Cap $60.83M
Overview Financials Dividend Achilles Therapeutics plc most recently reported annual revenue of $0, a net loss of $70.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2019 2020 2021 2022 2023 Revenue $0 $0 $0 $0 $0 Operating Profit $-14.0M $-34.0M $-64.0M $-78.0M $-75.0M Net Profit $-14.0M $-33.0M $-61.0M $-71.0M $-70.0M EPS $-20.48 $-0.82 $-2.13 $-1.82 $-1.74 Op Margin — — — — —
Balance Sheet (USD)
Metric 2019 2020 2021 2022 2023 Total Assets $105.0M $219.0M $317.0M $220.0M $161.0M Total Liabilities $4.0M $30.0M $28.0M $23.0M $19.0M Cash $98.0M $178.0M $266.0M $173.0M $132.0M Borrowings $0 $16.0M $12.0M $9.0M $5.0M
Cash Flow (USD)
Metric 2019 2020 2021 2022 2023 Operating Cash Flow $-14.0M $-25.0M $-59.0M $-60.0M $-48.0M Investing Cash Flow $-2.0M $-24.0M $-23.0M $-23.0M $-2.0M Financing Cash Flow $0 $0 $161.0M $0 $0 Net Cash Flow $87.0M $80.0M $89.0M $-93.0M $-42.0M Free Cash Flow $-15.0M $-37.0M $-67.0M $-67.0M $-50.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.07 EV / EBITDA 0.94 FCF Yield -81.46% Quick Ratio 8.57 Interest Coverage — Return 1Y — Return 3Y — Return 5Y —
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .